Irvine, California, and Freising, Germany, February 1, 2016 On June 30, 2015, DNX Biopharmaceuticals (“DNX”) of Irvine, California and XL-protein GmbH (“XLp”) of Freising, Germany, announced they would collaborate in the development and commercialization of novel long acting biopharma-ceutical products with financial terms undisclosed. Under this strategic collaboration, XLp contributes its half-life extension platform technology […]
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png00web28627236https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.pngweb286272362016-02-01 23:01:472016-09-25 17:09:47DNX Biopharmaceuticals and XL-protein Enter into a Shareholder Agreement to Develop and Commercialize Novel Long Acting Biopharmaceuticals.
Freising, Germany, and Chengdu, P.R. China, December 17, 2015 — XL-protein GmbH and Easton Pharmaceutical Co., Ltd. announced today that they have entered into a License, Development and Commercialization Agreement for novel, long-acting biopharmaceutical products to address a range of unmet needs in ophthalmology and potential further indications. Under this collaboration, XL-protein will apply its proprietary […]
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png00web28627236https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.pngweb286272362015-12-17 12:45:362016-09-25 17:11:40XL-protein and Easton Pharmaceutical sign license agreement to develop biopharmaceuticals using PASylation® technology
New Half-Life Extension Platform Technology Will Support the Development and Commercialization of Novel Therapeutic Proteins Addressing Unmet Needs in Immunology, Metabolism and Ophthalmology Irvine, CA and Freising, Germany, June 30, 2015 — DNX Biopharmaceuticals, Inc. (“DNX”) a company with a team of experienced industry professionals with a long and successful track record of developing and […]
DNX Biopharmaceuticals and XL-protein Enter into a Shareholder Agreement to Develop and Commercialize Novel Long Acting Biopharmaceuticals.
Irvine, California, and Freising, Germany, February 1, 2016 On June 30, 2015, DNX Biopharmaceuticals (“DNX”) of Irvine, California and XL-protein GmbH (“XLp”) of Freising, Germany, announced they would collaborate in the development and commercialization of novel long acting biopharma-ceutical products with financial terms undisclosed. Under this strategic collaboration, XLp contributes its half-life extension platform technology […]
XL-protein and Easton Pharmaceutical sign license agreement to develop biopharmaceuticals using PASylation® technology
Freising, Germany, and Chengdu, P.R. China, December 17, 2015 — XL-protein GmbH and Easton Pharmaceutical Co., Ltd. announced today that they have entered into a License, Development and Commercialization Agreement for novel, long-acting biopharmaceutical products to address a range of unmet needs in ophthalmology and potential further indications. Under this collaboration, XL-protein will apply its proprietary […]
DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharmaceutical Products
New Half-Life Extension Platform Technology Will Support the Development and Commercialization of Novel Therapeutic Proteins Addressing Unmet Needs in Immunology, Metabolism and Ophthalmology Irvine, CA and Freising, Germany, June 30, 2015 — DNX Biopharmaceuticals, Inc. (“DNX”) a company with a team of experienced industry professionals with a long and successful track record of developing and […]